Scientific Advisory Board

Our Scientific Advisory Board

The scientific advisors and founders of Alnylam are among the world’s leaders in RNAi research as well as broad aspects of medical research. Learn more about the accomplishments of each of our highly regarded scientists by selecting a name below.

Scientific Advisors

Phillip Sharp, PhD

Institute Professor, The Koch Institute for Integrative Cancer Research, MIT; former Director, McGovern Institute for Brain Research; Nobel Laureate; founder of Biogen, Inc. (now Biogen Idec, Inc.) and Alnylam; National Academy of Sciences.

Dennis Ausiello, MD

Director of the Center for Assessment Technology and Continuous Health (CATCH) and Physician‐in‐Chief Emeritus at Massachusetts General Hospital; Jackson Distinguished Professor of Clinical Medicine at Harvard Medical School; Director of Pfizer, Inc.

David Bartel, PhD

Member of the Whitehead Institute for Biomedical Research and Professor of Biology at MIT, Investigator of the Howard Hughes Medical Institute, noted RNA and RNAi expert, and a founder of Alnylam.

Nancy J. Brown, MD

Professor of Medicine and Pharmacology, Hugh J. Morgan Chair of the Department of Medicine at Vanderbilt University School of Medicine, among first team of scientists to report an increased risk of ACE inhibitor-associated angioedema among African-Americans; American Society for Clinical Investigation and the Association of American Physicians member; specialist in vascular biology and hypertension.

Muthiah (Mano) Manoharan, PhD

Senior Vice President, Innovation Chemistry and Distinguished Scientist at Alnylam; world-leading nucleic acid and bioconjugate chemist; author of more than 200 publications and over 300 abstracts, as well as the inventor of over 180 issued US patents.

Rachel Meyers, PhD

Former head of Research at Alnylam Pharmaceuticals and member of the Scientific Advisory Board at Editas Medicine. During her 13 years with Alnylam, Dr. Meyers played a key role in the advancement of both the RNAi platform and Alnylam’s RNAi therapeutic programs, from early discovery through clinical development. Dr. Meyers has worked closely with Alnylam’s business development and IP groups, playing an integral part in establishing important collaborations, and functioned as scientific lead in collaborations with Novartis, Takeda, Isis, Roche, and Genzyme.

Daniel J. Rader, MD

Professor of Medicine and Chief, Division of Translational Medicine and Human Genetics, at the Perelman School of Medicine at the University of Pennsylvania.

Paul Schimmel, PhD

Hahn Professor of Molecular Biology and Chemistry at Scripps Research Institute; National Academy of Sciences, American Academy of Arts and Sciences, and Institute of Medicine member; co-founder of Cubist, Alkermes; and Repligen, and a founder and member of the Board of Directors of Alnylam.

Markus Stoffel, MD, PhD

Professor for Metabolic Diseases at the Institute of Molecular Systems Biology, Swiss Federal Institute of Technology (ETH) in Zurich.


Receive news and updates on the work at Alnylam that affects you most.